What happened

Shares of biopharma Sangamo Therapeutics (NASDAQ:SGMO) rose nearly 15% today after the company received favorable coverage in multiple media outlets. Biotech thought leaders STAT Plus and Genetic Engineering & Biotechnology News published articles reminding readers that CRISPR isn't the only gene editing technology available as a potential treatment -- or cure -- for rare metabolic disorders and other genetic diseases.

In fact, the company's zinc finger nuclease (ZFN) technology made headlines weeks ago as the first gene editing tech to enter a clinical trial. CRISPR tech isn't expected to enter the clinic until next year, when Editas Medicine initiates a trial aiming to treat a rare eye disease.

As of 3:17 p.m. EDT, the stock had settled to a 12.3% gain.

A white gloved hand holding up a silver platter with DNA on it.

Image source: Getty Images.

So what

The articles are correct: It's true that there are multiple technology approaches with promising potential as gene editing therapies. That wasn't exactly a secret to investors before today. However, it's also true that CRISPR remains the easiest technology to engineer for precision, accuracy, and (importantly yet often overlooked) delivery into cells.

In fact, Sangamo Therapeutics has maintained firm control of the ZFN approach and another gene editing technology called TALEN for decades with little to show for it. If it weren't for the media craze surrounding CRISPR, then it's possible the company's gene editing approach would still be overlooked.

Then again, advances made with CRISPR in recent years have also inspired the company to make new advances for enhanced ZFN therapeutic candidates that are more accurate and precise than previous tech. So at least some of the recognition is warranted. 

Now what

Long story short, there's still potential for Sangamo Therapeutics to prove successful in the clinic and advance a ZFN-based therapeutic into the market. Investors shouldn't yet be concerned that the mere existence of CRISPR means it will become the de facto approach in gene editing. That said, the company has a long way to go before it can claim success with its technology platform.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.